Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387339 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTPDE2APDE1APDE1B | |
| SCHEMBL1959299 | 0.78 | PDE1A (0.58) | HPGDALDH1A1MAPTPDE2APDE1A | |
| SCHEMBL12820631 | 0.77 | MAPT (0.46) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7093373 | 0.75 | CYP2C9 (0.50) | HPGDALDH1A1PDE2APDE1APDE1B | |
| SCHEMBL515533 | 0.75 | CYP3A4 (0.62) | HPGDALDH1A1MAPTPDE2APDE1A | |
| SCHEMBL516430 | 0.71 | PDE2A (0.44) | HPGDALDH1A1MAPTPDE2APDE1A | |
| SCHEMBL461786 | 0.70 | PDE2A (0.62) | ALDH1A1PDE2APDE1APDE1BPDE1C | |
| Water SCHEMBL28799658 | 0.69 | PDE2A (0.60) | ALDH1A1PDE2APDE1APDE1BPDE1C | |
| SCHEMBL4621727 | 0.68 | PDE2A (0.51) | HPGDALDH1A1PDE2APDE1APDE1B | |
| SCHEMBL6458349 | 0.68 | PDE2A (0.38) | HPGDALDH1A1PDE2APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3217985-B1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| EP-3217984-B1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SELABTEC SCIENCES, SL (ES) | 2017-11-02 | — | — | US | claimed |
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2017-10-26 | — | — | US | claimed |
| EP-3217985-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| EP-3217984-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| WO-2016075288-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| WO-2016075285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| EP-3020403-A1 | Compounds for the treatment of myotonic dystrophy | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| EP-3020404-A1 | Caffeine for the treatment of myotonic dystrophy type 1 and type 2 | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | claimed |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | disclosed |
| EP-3217984-B1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | disclosed |
| WO-2001093831-A2 | LOW CARBOHYDRATE COMPOSITIONS, KITS THEREOF, AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001093847-A2 | COMPOSITIONS, KITS, AND METHODS FOR PROMOTING DEFINED HEALTH BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001005253-A1 | COMPOSITIONS, KITS, AND METHODS FOR PROVIDING AND MAINTAINING ENERGY AND MENTAL ALERTNESS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | SMN1; SMN2, TDP2, MTPN | HPGD 2785/4885ALDH1A1 1067/4885MAPT 161/4885 |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SMN1; SMN2, CPT1B, MTPN | HPGD 1516/4885ALDH1A1 647/4885MAPT 226/4885 |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | SMN1; SMN2, CPT1B, MTPN | HPGD 1516/4885ALDH1A1 647/4885MAPT 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.